Gan & Lee Pharmaceuticals announced after market close on October 8 that its insulin aspart injection, under the brand name Rapilin, has received drug registration approval in Ethiopia for the treatment of diabetes, with approval number 13984/14624/NMR/2026. The announcement showed that Ethiopia has a total population of about 130 million, with approximately 2.3 million people aged 20 to 79 living with diabetes in 2024, a prevalence rate of 3.6 percent. Currently, there are no insulin aspart products available in Ethiopia. As of June 30, 2026, Gan & Lee Pharmaceuticals has invested a cumulative 226.69 million yuan in research and development for the insulin aspart project. The product previously received authorization from the European Commission in May 2026, allowing it to be marketed in the European Union, Iceland, Liechtenstein, and Norway, and it has also obtained drug registration approval in Bolivia. In January 2026, the company's insulin glargine product received registration approval in Ethiopia. In the first half of 2026, Gan & Lee Pharmaceuticals achieved operating revenue of 2.223 billion yuan, up 7.56 percent year on year, and net profit attributable to the parent company of 610 million yuan, up 1.01 percent year on year, of which international revenue was 426 million yuan, up 92.33 percent year on year.
Gan & Lee Pharmaceuticals Co LtdGan & Lee received Ethiopian drug registration approval for its insulin aspart injection Rapilin, opening a new market with no existing insulin aspart products.
